TrialBMC medicine2022

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).

Guangjian Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.